Santarus CEO Gerald Proehl Sells 50,000 Shares (SNTS)
Santarus (NASDAQ:SNTS) CEO Gerald Proehl sold 50,000 shares of Santarus stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $22.19, for a total value of $1,109,500.00. Following the transaction, the chief executive officer now directly owns 28,425 shares of the company’s stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on SNTS. Analysts at Leerink Swann downgraded shares of Santarus (NASDAQ:SNTS) from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, August 22nd. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at JMP Securities raised their price target on shares of Santarus (NASDAQ:SNTS) from $27.00 to $31.00 in a research note to investors on Wednesday, August 7th. Finally, analysts at Zacks downgraded shares of Santarus (NASDAQ:SNTS) from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, July 25th. They now have a $27.80 price target on the stock.
Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $25.63.
Santarus (NASDAQ:SNTS) traded up 2.84% on Tuesday, hitting $22.78. 1,305,697 shares of the company’s stock traded hands. Santarus has a one year low of $8.47 and a one year high of $28.10. The stock’s 50-day moving average is $24.15 and its 200-day moving average is $21.16. The company has a market cap of $1.512 billion and a P/E ratio of 15.44.
Santarus (NASDAQ:SNTS) last announced its earnings results on Tuesday, August 6th. The company reported $0.94 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.18 by $0.76. The company had revenue of $89.40 million for the quarter, compared to the consensus estimate of $82.90 million. During the same quarter last year, the company posted $0.05 earnings per share. Santarus’s revenue was up 89.4% compared to the same quarter last year. On average, analysts predict that Santarus will post $1.26 earnings per share for the current fiscal year.
Santarus, Inc (NASDAQ:SNTS) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.